Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Expert Rev Pharmacoecon Outcomes Res
; 19(2): 203-212, 2019 Apr.
Article
in En
| MEDLINE
| ID: mdl-30251553
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Atrial Fibrillation
/
Stroke
/
Hemorrhage
/
Anticoagulants
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Country/Region as subject:
America do norte
Language:
En
Journal:
Expert Rev Pharmacoecon Outcomes Res
Year:
2019
Type:
Article
Affiliation country:
United States